Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption

Drug Development Research

Volumn 55, Issue 4, 2002, Pages 210-224

  Green, Jonathan R ^a   Rogers, Michael J ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Bisphosphonate; Bone resorption; Hypercalcemia of malignancy; Pamidronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTHRITIS; ARTICLE; BENIGN TUMOR; BONE ATROPHY; BONE CANCER; BONE METASTASIS; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; DOSE RESPONSE; DRUG ACTIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; MALIGNANT NEOPLASTIC DISEASE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PAGET BONE DISEASE; PROSTHESIS LOOSENING;

EID: 0036062211     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10071     Document Type: Article

References (105)

1. Adverse effects of bisphosphonates. A comparative review
2. Mineralisation defects with pamidronate therapy for Paget's disease
3. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
4. In vitro cytoredtictive effects on multiple myeloma cells induced by bisphosphonates
5. Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate
6. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
7. Visualisation of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
8. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
9. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
10. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
11. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
12. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
13. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
14. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
15. A dose-finding study of zoledronate in hypercalcemic cancer patients
16. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix
17. Effects of zoledronate on prostate cancer cells
18. Skeletal complications of malignancy
19. The clinical course of bone metastases from breast cancer
20. Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy
21. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
22. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
23. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
24. Bisphosphonates for controlling pain from metastatic bone disease
25. The systemic treatment of bone metastases
26. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
27. Effects of two novel bisphosphonates on bone cells in vitro
28. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
29. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway
30. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone
31. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro
32. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
33. Bisphosphonates inhibit breast cancer cell proliferation
34. Bisphosphonates induce breast cancer cell death in vitro
35. Bisphosphonates: Structure-activity relationships and therapeutic implications
36. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate
37. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by microcomputed tomography
38. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
39. Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties and biochemical markers in the ovariectomized rat
40. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models
41. The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo
42. Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone
43. Effects of 16-month zoledronate treatment on bone mechanical properties in the ovariectomized adult rhesus monkey
44. The effect of zoledronate on bone quality in a canine model as aseptic loosening of hip implant
45. Bone changes due to bisphosphonate treatment in a model of aseptic loosening
46. Non-primate models of osteoporosis
47. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
48. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
49. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
50. Primate models of osteoporosis
51. Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Maeaca faseicularis)
52. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
53. Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis
54. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
55. Bone loss in patients with rheumatoid arthritis
56. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: Experimental studies with the Walker carcinosarcoma 256
57. Prevention and therapy of tumor induced osteolysis by pharmacological antiolysis
58. Bisphosphonate treatment inhibits the growth of prostate cancer cells
59. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
60. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
61. Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms
62. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate
63. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
64. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
65. Oral bisphosphonates: A review of clinical use in patients with bone metastases
66. Zoledronic acid is superior to pamidronate in the treatment of hypercalcelmia of malignancy: A pooled analysis of two randomized, controlled clinical trials
67. Malignant bone pain: Pathophysiology and treatment
68. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat
69. Pathology of skeletal metastasis
70. The hypercalcemia of cancer: Clinical implications and pathogenic mechanisms
71. Zoledronate (CGP 42,446) suppresses turnover in cortical bone of the ovariectomized non-human primate
72. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
73. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment
74. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
75. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study
76. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis
77. Zoledronate (CGP 42′446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis
78. Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate)
79. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts
80. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum
81. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dietyostelium discoideum
82. Overview of bisphosphonates
83. Cellular and molecular mechanisms of action of bisphosphonates
84. The pharmacology of bisphosphonates and new insights into their mechanisms of action
85. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
86. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat
87. Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the Walker carcinosarcoma 256 rat model
88. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages
89. Bisphosphonates induce apoptosis in human breast cancer cell lines
90. Structure-activity relationships of various bisphosphonates
91. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
92. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
93. Antiresorptive dose-response relationships across three generations of bisphosphonates
94. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and nonhumoral groups
95. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
96. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
97. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships
98. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
99. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
100. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
101. Antiosteolytic properties of CGP 42446 in tumor osteolysis: Experimental findings with a new highly potent bisphosphonate
102. Protein prenylation: Molecular mechanisms and functional consequences
103. Comparative tolerability of drug therapies for hypercalcaemia of malignancy